07:00 , Mar 16, 2015 |  BC Week In Review  |  Clinical News

PEP-CMV: Phase I/II data

Researchers at Duke University (Durham, N.C.) reported data from a U.S. Phase I/II trial in 12 patients with newly diagnosed GBM showing that preconditioning the vaccine site with a tetanus/diphtheria toxoid antigen prior to vaccination...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Company News

Duke University, Annias Immunotherapeutics deal

Duke granted newco Annias exclusive, worldwide rights to develop and commercialize IP covering immune preconditioning technology and IP targeting cytomegalovirus (CMV) to treat cancer. The preconditioning technology is comprised of administering a tetanus/diphtheria toxoid antigen...
01:33 , Mar 13, 2015 |  BC Extra  |  Company News

Newco Annias debuts with glioblastoma vaccine

Immuno-oncology newco Annias Immunotherapeutics Inc. (Chapel Hill, N.C.) debuted with IP licensed from Duke University to a clinical-stage vaccine that targets solid tumors and a method to boost the vaccine's activity. CEO Reiner Laus told...